Multiple sclerosis (Houndmills, Basingstoke, England) · 2025
Prevalence of multiple sclerosis and disease-modifying therapy use in older adults in the United States, 2011-2021.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Jieni, Hutton George J, Aparasu Rajender R
Аннотация
BACKGROUND: With advances in disease-modifying therapies (DMTs), patients with multiple sclerosis (MS) are living longer.
OBJECTIVE: This study examined MS prevalence and DMT use among older adults 65 years and above in the United States.
METHODS: The study analyzed 2011-2021 Medicare fee-for-service claims data.
RESULTS: The prevalence rate of MS in older adults increased by 15.49%, from 210.55 (per 100,000) in 2011 to 243.17 in 2021. Women comprised 75% of the aging MS population, and 90% were White. Over half were prescribed DMTs, mainly interferon-beta and glatiramer acetate.
CONCLUSIONS: The study found an increasing prevalence of MS among older adults in the United States over the past decade, with over half using DMTs. Our findings highlight the need for increasing geriatric care for MS.
OBJECTIVE: This study examined MS prevalence and DMT use among older adults 65 years and above in the United States.
METHODS: The study analyzed 2011-2021 Medicare fee-for-service claims data.
RESULTS: The prevalence rate of MS in older adults increased by 15.49%, from 210.55 (per 100,000) in 2011 to 243.17 in 2021. Women comprised 75% of the aging MS population, and 90% were White. Over half were prescribed DMTs, mainly interferon-beta and glatiramer acetate.
CONCLUSIONS: The study found an increasing prevalence of MS among older adults in the United States over the past decade, with over half using DMTs. Our findings highlight the need for increasing geriatric care for MS.